1887

Abstract

Nitrofurantoin is one of the preferred antibiotics in the treatment of uropathogenic multidrug-resistant (MDR) infections. However, resistance to nitrofurantoin in extensively drug-resistant (XDR) bacteria has severely limited the treatment options.

Information related to co-resistance or collateral sensitivity (CS) with reference to nitrofurantoin resistant bacteria is limited.

To study the potential of nitrofurantoin resistance as an indicator of the XDR phenotype in .

One hundred (45 nitrofurantoin-resistant, 21 intermediately resistant and 34 nitrofurantoin-susceptible) were analysed in this study. Antibiotic susceptibility testing (AST) against nitrofurantoin and 17 other antimicrobial agents across eight different classes was performed by using the Vitek 2.0 system. The isolates were screened for the prevalence of acquired antimicrobial resistance (AMR) and efflux pump genes by PCR.

In total, 51 % of nitrofurantoin-resistant and 28 % of intermediately nitrofurantoin resistant isolates exhibited XDR characteristics, while only 3 % of nitrofurantoin-sensitive isolates were XDR (=0.0001). Significant co-resistance was observed between nitrofurantoin and other tested antibiotics (β-lactam, cephalosporin, carbapenem, aminoglycoside and tetracycline). Further, the prevalence of AMR and efflux pump genes was higher in the nitrofurantoin-resistant strains compared to the susceptible isolates. A strong association was observed between nitrofurantoin resistance and the presence of , , , and genes. Tigecycline (84 %) and colistin (95 %) were the only antibiotics to which the majority of the isolates were susceptible.

Nitrofurantoin resistance could be an indicator of the XDR phenotype among , harbouring multiple AMR and efflux pump genes. Tigecycline and colistin are the only antibiotics that could be used in the treatment of such XDR infections. A deeper understanding of the co-resistance mechanisms in XDR pathogens and prescription of AST-based appropriate combination therapy may help mitigate this problem.

Funding
This study was supported by the:
  • ICMR (Award 2020-5867)
    • Principle Award Recipient: BulagondaEswarappa Pradeep
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001347
2021-04-08
2021-06-17
Loading full text...

Full text loading...

References

  1. Osei Sekyere J. Genomic insights into nitrofurantoin resistance mechanisms and epidemiology in clinical Enterobacteriaceae. Future Sci OA 2018; 4:FSO293–FSO [View Article][PubMed]
    [Google Scholar]
  2. Huttner A, Verhaegh EM, Harbarth S, Muller AE, Theuretzbacher U et al. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother 2015; 70:2456–2464 [View Article][PubMed]
    [Google Scholar]
  3. Shanmugam D, Esak SB, Narayanaswamy A. Molecular characterisation of nfsA gene in nitrofurantoin resistant uropathogens. J Clin Diagn Res 2016; 10:DC05–DC9 [View Article][PubMed]
    [Google Scholar]
  4. Vervoort J, Xavier BB, Stewardson A, Coenen S, Godycki-Cwirko M et al. An in vitro deletion in ribE encoding lumazine synthase contributes to nitrofurantoin resistance in Escherichia coli . Antimicrob Agents Chemother 2014; 58:7225–7233 [View Article][PubMed]
    [Google Scholar]
  5. Ho P-L, Ng K-Y, Lo W-U, Law PY, Lai EL-Y et al. Plasmid-mediated OqxAB is an important mechanism for nitrofurantoin resistance in Escherichia coli . Antimicrob Agents Chemother 2016; 60:537–543 [View Article][PubMed]
    [Google Scholar]
  6. Chen X, Zhang W, Pan W, Yin J, Pan Z et al. Prevalence of qnr, aac(6')-Ib-cr, qepA, and oqxAB in Escherichia coli isolates from humans, animals, and the environment. Antimicrob Agents Chemother 2012; 56:3423–3427 [View Article][PubMed]
    [Google Scholar]
  7. Sandegren L, Lindqvist A, Kahlmeter G, Andersson DI. Nitrofurantoin resistance mechanism and fitness cost in Escherichia coli . J Antimicrob Chemother 2008; 62:495–503 [View Article][PubMed]
    [Google Scholar]
  8. Li J, Zhang H, Ning J, Sajid A, Cheng G et al. The nature and epidemiology of OqxAB, a multidrug efflux pump. Antimicrob Resist Infect Control 2019; 8:44 [View Article][PubMed]
    [Google Scholar]
  9. Perez F, Rudin SD, Marshall SH, Coakley P, Chen L et al. OqxAB, a quinolone and olaquindox efflux pump, is widely distributed among multidrug-resistant Klebsiella pneumoniae isolates of human origin. Antimicrob Agents Chemother 2013; 57:4602–4603 [View Article][PubMed]
    [Google Scholar]
  10. Rafii F, Hansen EB. Isolation of nitrofurantoin-resistant mutants of nitroreductase-producing Clostridium sp. strains from the human intestinal tract. Antimicrob Agents Chemother 1998; 42:1121–1126 [View Article][PubMed]
    [Google Scholar]
  11. Amladi A, Abirami B, Devi S, Sudarsanam T, Kandasamy S et al. Susceptibility profile, resistance mechanisms & efficacy ratios of fosfomycin, nitrofurantoin & colistin for carbapenem-resistant Enterobacteriaceae causing urinary tract infections. Indian Journal of Medical Research 2019; 149:185–191
    [Google Scholar]
  12. Roemhild R, Linkevicius M, Andersson DI. Molecular mechanisms of collateral sensitivity to the antibiotic nitrofurantoin. PLoS Biol 2020; 18:e3000612 [View Article][PubMed]
    [Google Scholar]
  13. Pouwels KB, Muller-Pebody B, Smieszek T, Hopkins S, Robotham JV. Selection and co-selection of antibiotic resistances among Escherichia coli by antibiotic use in primary care: An ecological analysis. PLoS One 2019; 14:e0218134-e [View Article][PubMed]
    [Google Scholar]
  14. Imamovic L, Sommer MOA. Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. Sci Transl Med 2013; 5:204ra132-204ra132 [View Article][PubMed]
    [Google Scholar]
  15. Basak S, Singh P, Rajurkar M. Multidrug resistant and extensively drug resistant bacteria: a study. J Pathog 2016; 2016:4065603 [View Article][PubMed]
    [Google Scholar]
  16. Bhatt P, Tandel K, Shete V, Rathi KR. Burden of extensively drug-resistant and pandrug-resistant Gram-negative bacteria at a tertiary-care centre. New Microbes New Infect 2015; 8:166–170 [View Article][PubMed]
    [Google Scholar]
  17. Funke G, Monnet D, deBernardis C, von Graevenitz A, Freney J. Evaluation of the Vitek 2 system for rapid identification of medically relevant gram-negative rods. J Clin Microbiol 1998; 36:1948–1952 [View Article][PubMed]
    [Google Scholar]
  18. Taneja N, Sharma M. Antimicrobial resistance in the environment: the Indian scenario. Indian J Med Res 2019; 149:119–128 [View Article][PubMed]
    [Google Scholar]
  19. Nikaido H. Multidrug resistance in bacteria. Annu Rev Biochem 2009; 78:119–146 [View Article][PubMed]
    [Google Scholar]
  20. Kashanian J, Hakimian P, Blute M, Wong J, Khanna H et al. Nitrofurantoin: the return of an old friend in the wake of growing resistance. BJU Int 2008; 102:1634–1637 [View Article][PubMed]
    [Google Scholar]
  21. Ingalsbe ML, Wojciechowski AL, Smith KA, Mergenhagen KA. Effectiveness and safety of nitrofurantoin in outpatient male veterans. Ther Adv Urol 2015; 7:186–193 [View Article][PubMed]
    [Google Scholar]
  22. Gardiner BJ, Stewardson AJ, Abbott IJ, Peleg AY. Nitrofurantoin and fosfomycin for resistant urinary tract infections: old drugs for emerging problems. Aust Prescr 2019; 42:14–19 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001347
Loading
/content/journal/jmm/10.1099/jmm.0.001347
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error